Department of Medicine, Queen's University, Kingston, Canada.
Haemophilia. 2014 May;20 Suppl 4(0 4):71-5. doi: 10.1111/hae.12402.
Rare bleeding disorders (RBDs) are inherited deficiencies of coagulation factors such as fibrinogen, factor (F) II, FV, FVII, combined FV+FVIII, FX, FXI and FXIII. These disorders usually have a low prevalence in the general population and constitute approximately 3-5% of all coagulation disorders. However, in some countries they may have the same prevalence as haemophilia B due to the practice of consanguineous marriage. The clinical picture of RBDs is highly variable and can vary markedly from mild to severe, making both diagnosis and optimal treatment quite challenging. This review focuses on: (i) the efforts to establish a bleeding assessment tool adequate to RBDs, (ii) the optimal management of patients affected with FXI deficiency and (iii) the correlation between clinical severity and laboratory diagnosis when determining the minimum coagulant activity required to prevent bleeding in each RBD.
罕见出血性疾病(RBDs)是纤维蛋白原、因子(F)II、FV、FVII、FV+FVIII 联合、FX、FXI 和 FXIII 等凝血因子遗传性缺乏所致。这些疾病在普通人群中的发病率通常较低,约占所有凝血障碍的 3-5%。然而,在某些国家,由于近亲结婚的做法,它们的患病率可能与乙型血友病相同。RBDs 的临床表现高度可变,从轻度到重度差异很大,这使得诊断和最佳治疗都极具挑战性。本综述重点介绍:(i)建立一种适合 RBDs 的出血评估工具的努力,(ii)FXI 缺乏症患者的最佳管理,以及(iii)在确定每个 RBD 预防出血所需的最低凝血活性时,临床严重程度与实验室诊断之间的相关性。